Biohit Oyj October 9, 2013 at 5 P.M. local time (EET)
Biohit will release its financial statements for 2013 on Thursday 27th of February 2014 at 9:30 AM.
Biohit Oyj’s Annual General Meeting has been planned for Monday 14th of April 2014 at 3:00 PM in Helsinki, Finland. The Board of Directors will call the General Meeting at a later date.
Company will publish three interim reports in 2014, based on the following schedule:
The published economic reports and other stock exchange releases will be available on Biohit's website at www.biohithealthcare.com/investors. The website also contains an online form for ordering electronic copies, which will be e-mailed to you.
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit's Series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com.